Natco Pharma Limited is an Indian pharmaceutical company headquartered in Hyderabad, Telangana. The company is engaged in the development, manufacturing, and marketing of finished dosage formulations and active pharmaceutical ingredients (APIs), with a notable presence in oncology, hepatology, and other speciality therapeutic segments. It is listed on the BSE and the NSE.
| Type | Public limited company |
|---|---|
| Industry | Pharmaceuticals |
| Headquarters | Hyderabad, Telangana, India |
| Founder | V. C. Nannapaneni |
| Listings | BSE, NSE |
| Key products | Oncology formulations, antiviral drugs, APIs, generics |
Natco Pharma was founded by V. C. Nannapaneni and began operations in Hyderabad. From an initial focus on contract manufacturing and generics, the company progressively built capabilities in complex generics and speciality therapeutic areas, particularly oncology. It has since expanded its operations to include APIs, finished dosage forms, and intellectual property–led product development.
The company operates several manufacturing facilities in India, including units in Telangana and Andhra Pradesh, along with research and development centres focused on formulations and process chemistry.
Natco Pharma drew international attention in 2012 when the Controller General of Patents, Designs and Trade Marks granted it India's first compulsory licence under the Indian Patents Act. The licence allowed Natco to manufacture and sell a generic version of sorafenib tosylate, an anti-cancer drug originally marketed by Bayer under the brand name Nexavar. The decision was widely discussed in international forums on access to medicines and pharmaceutical patent law.
Natco supplies products to the Indian domestic market as well as international markets, including the United States, Canada, Europe, Brazil, and other emerging economies. In the United States, it has marketed selected generics through partnership arrangements with larger generic distributors. The company also operates a presence in Canada through a subsidiary serving the local pharmaceutical market.
Natco Pharma is regarded as one of the more research-driven mid-sized Indian pharmaceutical firms, particularly known for its complex generics strategy and its role in landmark Indian patent law cases. Its activities have contributed to wider debates on the balance between patent protection and access to affordable medicines in developing countries.